Akari Therapeutics, Plc (AKTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AKTX
- Company Akari Therapeutics, Plc
- Price $18.27
- Changes Percentage 255.45
- Change 13.13
- Day Low $8.58
- Day High $18.99
- Year High $56.8
- Year Low $3.02
- Market Cap $20,911,604
- Price Avg 50 EMA (D) $5.46
- Price Avg 200 EMA (D) $17.98
- Exchange NASDAQ
- Volume 31,838,547
- Average Volume 670,108
- Open $9.92
- Previous Close $5.14
- EPS -2.58
- PE -7.08
- Earnings Announcement 2026-08-18 12:00:00
- Shares Outstanding $1,144,587
Company brief: AKARI THERAPEUTICS, PLC (AKTX )
- Healthcare
- Biotechnology
- Dr. Samir Rashmikant Patel M.D.
- https://www.akaritx.com
- GB
- N/A
- 01-06-2014
- US00972G2075
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
AKTX Corporation News
Akari Therapeutics Stock Jumps On Promising Preclinical Data
benzinga.com -- Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pa...
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
globenewswire.com -- An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data sup...
Akari Therapeutics Announces $5.5 Million Private Placement Offering
globenewswire.com -- TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing ...